India Equity Research | Building Materials June 27, 2020 **Result Update**

Kajaria Ceramics

Refer to important disclosures at the end of this report

Lower volumes to impact margins, but balance sheet to improve further

CMP: Rs 401 as of (June 27, 2020) TP: Rs 389 (▼) 12 months

Rating: HOLD (■)

Upside: (3.0) %

POLL 2020 We appreciate your support in the Asiamoney Brokers Poll 2020

- Q4 results were impacted by nationwide lockdowns, leading to a 19% yoy volume decline (vs. estimate of 12% fall). EBITDA was at Rs934mn vs. our estimate of Rs1,037mn and OPM stood at 14.3% vs. estimate of 14.5%.
- Key positives: 1) Gross margin improvement of 2.7pp yoy/78bps gog to 41.4% 2) 11 days improvement in receivables days. Key negatives: 1) Volume decline of 19% yoy 2) realization decline of 1.1% yoy 3) 13 days increase in inventory days in FY20.
- Management indicated that sales volumes were at 35%/50-60% of last year's volumes in May/Jun'20. Capacity utilization in Jul'20 should reach to 70%. Current gas prices are 10-12% lower than the Q4 average. There will not be any major capex in FY21.
- Q1FY21 sales volumes should be at 30-35% of last year's volumes and we now factor in a volume decline of 15% yoy in FY21E. EBITDA estimates are reduced by 40%/25% for FY21/22E. We introduce FY23 estimates and maintain the Hold rating on the stock.

Lockdowns hit volumes; gross margins improve: Q4 performance was hit by lockdowns and the firm reported a 19% yoy volume fall. In FY20, volume declined 2.8% yoy. Realization fell 1.1% yoy/0.8% gog. Prices of GVT and PVT tiles were under pressure as Morbi-based players tried to push volumes into markets to meet their liquidity requirements. Revenue from Sanitary ware/Bath fittings fell 22.1% yoy. Realization from own manufactured products fell 4.5% yoy, but that of JV products rose 5.2% yoy. Gas prices rose 6-7% qoq, impacting energy costs (up 4.5% yoy/3.3% qoq). Gross margin rose 2.7pp yoy/78bps qoq to 41.4%. EBITDA fell 24.1% yoy and OPM declined 76bps yoy to 14.3%. Adjusted profit after MI fell 27.9% yoy.

Reduce estimates; maintain Hold: Tiles demand was hit by lockdowns and recovery is expected only in H2FY21. Management said that sales volumes in May/Jun'20 were at 35%/50-60% of last year's volumes. We cut volume estimates by 26.3%/18.7% for FY21/22E. Management indicated cost reduction measures across verticals and expects costs savings of Rs800mn in FY21. We cut EBITDA by 40.3%/25% for FY21/22E. Gas prices has fallen by Rs3-4/scm (average price Rs31/scm in Q4); however, the benefits would mostly be reflected in Q2FY21 as the firm had inventory at FY20-end. Management does not expect much pressure on Tiles prices due to liquidity issues faced by Morbi players. Capex in FY21E is likely to be limited at Rs300-400mn vs. Rs1.2bn in FY20. Receivable days improved to 50 vs. 61 in FY19, but inventory days rose by 13 to 65 in FY20. ROE is likely to be at 13.3%/14.2% in FY22/23E vs. 15.5% in FY20. Though near-term outlook remains challenging, we believe that it will continue to command premium multiples due to its leadership position and B/S strength (net cash should improve to Rs3.8bn/Rs6.1bn/Rs8.3bn in FY21/22/23E vs. Rs1.1bn in FY20). We introduce FY23 estimates and maintain Hold, with a revised TP of Rs389 (22x mid-FY23E EPS). Key risks to our call include a steep recovery in tiles demand/prices.

Please see our sector model portfolio (Emkay Alpha Portfolio): Cement & Building Materials (Page 9)

Financial Snapshot (Consolidated)

(Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	29,562	28,080	24,540	29,845	32,982
EBITDA	4,495	4,159	3,078	4,477	5,106
EBITDA Margin (%)	15.2	14.8	12.5	15.0	15.5
APAT	2,314	2,554	1,520	2,573	3,051
EPS (Rs)	14.6	16.1	9.6	16.2	19.2
EPS (% chg)	4.2	10.4	(40.5)	69.3	18.6
ROE (%)	15.8	15.5	8.6	13.3	14.2
P/E (x)	27.6	25.0	42.0	24.8	20.9
EV/EBITDA (x)	13.9	15.1	19.5	12.9	10.9
P/BV (x)	4.0	3.7	3.5	3.1	2.8

FARS

Your success is our success

Change in Estimates		
EPS Chg FY21E/FY22E	E (%)	(50)/(30)
Target Price change (%)	(23.4)
Target Period (Months)		12
Previous Reco		HOLD
Emkay vs Consensus		
EPS Estin	nates	
	FY21E	FY22E
Emkay	9.6	16.2
Consensus	15.8	20.2
Mean Consensus TP (1	2M)	Rs 458
Stock Details		
Bloomberg Code		KJC IN
Face Value (Rs)		1
Shares outstanding (mr	ı)	159
52 Week H/L		606 / 295
M Cap (Rs bn/USD bn)		64 / 0.84
Daily Avg Volume (nos.)	4,82,623
Daily Avg Turnover (US	\$ mn)	2.3
Shareholding Pattern	Mar '20	
-		1

J	
Promoters	47.6%
FIIs	23.1%
DIIs	14.9%
Public and Others	14.4%

Price Performance												
(%)	1 M	3M	6M	12M								
Absolute	26	6	(23)	(32)								
Rel. to Nifty	9	(12)	(10)	(22)								

Relative price chart



Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

Sanjeev Kumar Singh

sanjeev.singh@emkayglobal.com +91 22 6612 1255

Gurpreet Kaur


gurpreet.kaur@emkayglobal.com +91 22 6612 1285

Source: Company, Emkay Research


Enkay Research is also available on www.enkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.


Story in Charts

Exhibit 1: Volume declined by 19% yoy/ 10.8% qoq





Source: Company, Emkay Research





Source: Company, Emkay Research





Source: Company, Emkay Research






Exhibit 2: Volume mix: a shift toward low-margin trading segment

Source: Company, Emkay Research





Source: Company, Emkay Research






Exhibit 7: Actual vs estimates (Q4FY20)

(in Doma)	Actual		Estima		Estimate	% vari	ation	Comment
(in Rs mn)	Actual	Emkay	Consensus	Emkay	Consensus	Comment		
Sales	6,520	7,153	7,084	-8.8%	-8.0%	Led by lower-than-estimated volumes		
EBITDA	934	1,037	1,005	-10.0%	-7.1%	Led by lower volumes/higher energy costs		
EBITDA, margin	14.3%	14.5%	14.2%					
PAT	478	553	556	-13.5%	-14.0%	Impact of lower operating profit		

Source: Company, Emkay Research, Bloomberg

Exhibit 8: Quarterly Results

Rs mn	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20	YoY (%)	QoQ (%)	FY20	FY19	YoY (%)
Revenue	8,153	7,000	7,147	7,413	6,520	(20.0)	(12.0)	28,080	29,562	(5.0)
Operating Expenditure	6,924	5,941	6,095	6,300	5,587	(19.3)	(11.3)	23,922	25,067	(4.6)
as % of sales	84.9	84.9	85.3	85.0	85.7			85.2	84.8	
Consumption of RM	3,546	2,805	2,906	2,893	2,406	(32.1)	(16.8)	11,011	11,464	(3.9)
as % of sales	43.5	40.1	40.7	39.0	36.9			39.2	38.8	
Power & Fuel	1,457	1,343	1,374	1,511	1,416	(2.8)	(6.2)	5,644	6,162	(8.4)
as % of sales	17.9	19.2	19.2	20.4	21.7			20.1	20.8	
Employee expenses	888	883	888	930	869	(2.2)	(6.6)	3,569	3,455	3.3
as % of sales	10.9	12.6	12.4	12.5	13.3			12.7	11.7	
Other expenses	1,034	910	925	967	896	(13.4)	(7.3)	3,698	3,987	(7.3)
as % of sales	12.7	13.0	12.9	13.0	13.7			13.2	13.5	
EBITDA	1,229	1,059	1,052	1,113	934	(24.1)	(16.1)	4,159	4,495	(7.5)
Depreciation	217	258	262	278	283	30.7	2.0	1,081	891	21.4
EBIT	1,013	801	791	835	650	(35.8)	(22.2)	3,078	3,604	(14.6)
Other Income	65	53	68	51	69	6.0	34.9	242	180	33.9
Interest	33	45	52	48	49	50.8	1.9	195	156	25.1
PBT	1,045	809	807	838	670	(35.9)	(20.1)	3,124	3,629	(13.9)
Total Tax	362	305	(124)	226	192	(47.0)	(15.0)	599	1,293	(53.7)
Adjusted PAT	683	503	931	613	478	(30.0)	(21.9)	2,525	2,336	8.1
(Profit)/loss from JV's/Ass/MI	9	(6)	(1)	(3)	(8)	(189.5)	175.0	-18	22	(182.6)
APAT after MI	674	510	932	615	486	(27.9)	(21.0)	2,543	2,314	9.9
Extra ordinary items	14	-	-	-	-			0	48	(100.0)
Reported PAT	689	510	932	615	486	(29.4)	(21.0)	2,543	2,363	7.6
Adjusted EPS	4.2	3.2	5.9	3.9	3.1	(27.9)	(21.0)	16.0	14.6	9.9
Margins (%)						(bps)	(bps)			(bps)
Gross margin	38.6	40.7	40.1	40.6	41.4	273	78	40.7	40.4	31
EBIDTA	15.1	15.1	14.7	15.0	14.3	(76)	(70)	14.8	15.2	(40)
EBIT	12.4	11.4	11.1	11.3	10.0	(245)	(130)	11.0	12.2	(123)

Source: Company, Emkay Research

12.0

8.3

34.7

10.8

7.3

37.8

Exhibit 9: Volume Summary

EBT

PAT

Effective Tax rate

Sales Volumes-mn sqm	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20	YoY (%)	QoQ (%)	FY20	FY19	YoY (%)
Own Manufacturing	11.5	10.9	10.9	11.3	10.0	(13.1)	(11.8)	43.1	44.4	(2.9)
JVs	6.2	4.4	4.7	5.2	4.2	(32.9)	(18.8)	18.5	21.3	(13.1)
Trading	4.8	4.4	4.1	4.0	4.1	(15.1)	2.8	16.5	14.7	12.4
Total sales volumes	22.5	19.6	19.8	20.4	18.2	(19.0)	(10.8)	78.1	80.3	(2.8)

10.6

8.3

26.9

9.2

7.5

28.6

(280)

(82)

(602)

(140)

(85)

172

10.3

9.1

19.2

11.7

7.8

35.6

(140)

123

(1,645)

10.3

13.0

(15.4)

Exhibit 10: Revenue Trend

Revenue Mix (Rs mn)	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20	YoY (%)	QoQ (%)	FY20	FY19	YoY (%)
Own Manufacturing	4,190	3,842	3,909	3,974	3,480	(16.9)	(12.4)	15,204	16,536	(8.1)
JVs	1,985	1,402	1,487	1,673	1,402	(29.4)	(16.2)	5,965	6,842	(12.8)
Trading	1,377	1,265	1,256	1,190	1,169	(15.1)	(1.7)	4,879	4,167	17.1
Sanitaryware / faucets	528	410	426	495	411	(22.1)	(16.9)	1,742	1,848	(5.7)
Plywood	73	81	70	81	58	(20.9)	(28.6)	289	168	71.9
Revenue	8,153	7,000	7,147	7,413	6,520	(20.0)	(12.0)	28,080	29,562	(5.0)

Source: Company, Emkay Research

Exhibit 11: Realization trend

Realization / sqm	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20	YoY (%)	QoQ (%)	FY20	FY19	YoY (%)
Own Manufacturing	365	354	358	351	348	(4.5)	(0.7)	353	373	(5.3)
JVs	318	317	316	324	335	5.2	3.2	323	322	0.3
Trading	288	291	303	301	288	(0.0)	(4.4)	296	284	4.2
Blended Realization	335	331	337	334	332	(1.1)	(0.8)	334	343	(2.7)

Source: Company, Emkay Research

Changes in estimates

We have reduced tiles volume estimates by 26.3%/18.7% for FY21/22E as the recovery in demand in expected only in H2FY21E. Management indicated that sales volumes in May/Jun'20 was at 35%/50-60% of last year's volumes. We now factor in a volume decline of 15% yoy in FY21E, however, we expect a volume growth of 20% in FY22E. Our OPM estimate for FY21/22E stands at 12.5%/15% vs. 15.5%/16% earlier. This leads to EBITDA reduction of 40.3%/25% for FY21/22E.

We have also introduced FY23E estimates wherein we factor in a volume/realization growth of 8%/1% yoy. Revenue estimate for FY23E is Rs33bn, growth of 10.5% yoy. OPM estimate for FY23E is 15.5% vs. 15% for FY22E. EBITDA estimate for FY23E is Rs5.1bn, growth of 14.1% yoy. Profit estimate for FY23E is Rs3.1n, growth of 18.6% yoy.

Exhibit 12: Change in estimates

Particulars (Rs mn)		FY21E			FY23E		
	Earlier	Revised	Chg (%)	Earlier	Revised	Chg (%)	Introducing
Sales	33,181	24,540	(26.0)	37,275	29,845	(19.9)	32,982
EBIDTA	5,153	3,078	(40.3)	5,968	4,477	(25.0)	5,106
EBIDTA (%)	15.5%	12.5%	(299)	16.0%	15.0%	(101)	15.5%
Net Profit	3,059	1,520	(50.3)	3,670	2,573	(29.9)	3,051
EPS (Rs)	19.2	9.6	(50.3)	23.1	16.2	(29.9)	19.2

Source: Company, Emkay Research

Exhibit 13: Key Assumptions						
Parameters	FY18	FY19	FY20	FY21E	FY22E	FY23E
Sales Volumes (msm)	72	80	78	66	80	86
Volume growth (yoy)	5.6%	12.2%	-2.8%	-15.0%	20.0%	8.0%
Average Realization (Rs/sqmt)	359	345	337	341	348	354
Realization growth (yoy)	-4.4%	-3.9%	-2.3%	0.0%	1.0%	1.0%
EBITDA margins (%)	16.8%	15.2%	14.8%	12.5%	15.0%	15.5%

Source: Company, Emkay Research

Exhibit 14: Peer Valuation

Com	Rs bn	EV/EBITDA (x)		ROCE (%)			EPS (Rs)			P/E (x)			
Company	Мсар	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E
Kajaria Ceramics	63.8	19.5	12.9	10.9	10.9	16.7	17.9	9.6	16.2	19.2	42.0	24.8	20.9
Somany Ceramics	5.3	9.2	5.8	4.9	3.9	8.2	9.7	-0.8	8.8	12.3	-164.7	14.4	10.2
Century Plyboards	26.8	7.1	6.3	5.6	22.2	22.8	22.3	10.0	11.4	12.6	12.1	10.6	9.6

Exhibit 15: 1-yr forward EV/EBITDA chart





Exhibit 16: 1-yr forward P/E chart



Source: Company, Emkay Research

Key Financials (Consolidated)

Income Statement

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	29,562	28,080	24,540	29,845	32,982
Expenditure	25,067	23,921	21,461	25,368	27,876
EBITDA	4,495	4,159	3,078	4,477	5,106
Depreciation	891	1,081	1,173	1,221	1,282
EBIT	3,604	3,078	1,905	3,256	3,824
Other Income	180	242	286	330	383
Interest expenses	156	195	162	132	102
РВТ	3,629	3,125	2,029	3,454	4,105
Тах	1,293	589	511	870	1,035
Extraordinary Items	(48)	0	0	0	0
Minority Int./Income from Assoc.	22	(18)	(2)	10	20
Reported Net Income	2,265	2,554	1,520	2,573	3,051
Adjusted PAT	2,314	2,554	1,520	2,573	3,051

Balance Sheet

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Equity share capital	159	159	159	159	159
Reserves & surplus	15,590	16,984	18,120	20,119	22,403
Net worth	15,749	17,143	18,279	20,278	22,562
Minority Interest	659	637	635	645	665
Loan Funds	1,203	1,182	982	782	582
Net deferred tax liability	1,059	716	716	716	716
Total Liabilities	18,671	19,678	20,612	22,421	24,525
Net block	10,778	11,948	11,175	10,753	10,471
Investment	3	101	101	101	101
Current Assets	12,003	12,056	13,813	16,139	18,734
Cash & bank balance	2,524	2,252	4,803	6,901	8,837
Other Current Assets	0	0	0	0	0
Current liabilities & Provision	5,048	4,693	4,777	4,872	5,081
Net current assets	6,955	7,363	9,036	11,266	13,652
Misc. exp	0	0	0	0	0
Total Assets	18,671	19,678	20,612	22,421	24,525

Cash Flow

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
PBT (Ex-Other income) (NI+Dep)	3,580	3,125	2,029	3,454	4,105
Other Non-Cash items	120	27	0	0	0
Chg in working cap	(117)	(993)	878	(132)	(450)
Operating Cashflow	3,174	2,244	3,731	3,805	4,005
Capital expenditure	(1,139)	(1,213)	(434)	(800)	(1,000)
Free Cash Flow	2,034	1,031	3,297	3,005	3,005
Investments	1	(90)	0	0	0
Other Investing Cash Flow	0	0	0	0	0
Investing Cashflow	(2,609)	(901)	(434)	(800)	(1,000)
Equity Capital Raised	(6)	3	0	0	0
Loans Taken / (Repaid)	(404)	(104)	(200)	(200)	(200)
Dividend paid (incl tax)	(575)	(1,150)	(383)	(575)	(766)
Other Financing Cash Flow	0	0	0	0	0
Financing Cashflow	(1,141)	(1,404)	(746)	(907)	(1,069)
Net chg in cash	(576)	(60)	2,551	2,098	1,936
Opening cash position	798	221	161	2,712	4,810
Closing cash position	2,524	2,252	4,803	6,901	8,837

Profitability (%)	FY19	FY20	FY21E	FY22E	FY23E
EBITDA Margin	15.2	14.8	12.5	15.0	15.5
EBIT Margin	12.2	11.0	7.8	10.9	11.6
Effective Tax Rate	35.6	18.9	25.2	25.2	25.2
Net Margin	7.9	9.0	6.2	8.7	9.3
ROCE	21.2	17.3	10.9	16.7	17.9
ROE	15.8	15.5	8.6	13.3	14.2
RoIC	23.1	19.1	11.7	21.3	25.2
Per Share Data (Rs)	FY19	FY20	FY21E	FY22E	FY23E
EPS	14.6	16.1	9.6	16.2	19.2
CEPS	20.2	22.9	16.9	23.9	27.2
BVPS	99.1	107.8	115.0	127.5	141.9
DPS	3.0	3.0	2.0	3.0	4.0
Valuations (x)	FY19	FY20	FY21E	FY22E	FY23E
PER	27.6	25.0	42.0	24.8	20.9
P/CEPS	19.9	17.5	23.7	16.8	14.7
P/BV	4.0	3.7	3.5	3.1	2.8
EV / Sales	2.1	2.2	2.4	1.9	1.7
EV / EBITDA	13.9	15.1	19.5	12.9	10.9
Dividend Yield (%)	0.8	0.8	0.5	0.8	1.0
Gearing Ratio (x)	FY19	FY20	FY21E	FY22E	FY23E
Net Debt/ Equity	(0.1)	(0.1)	(0.2)	(0.3)	(0.4)
Net Debt/EBIDTA	(0.3)	(0.1)	(1.2)	(1.4)	(0.4)
Working Cap Cycle (days)	54.7	66.4	63.0	53.4	53.3
Growth (%)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	9.1	(5.0)	(12.6)	21.6	10.5
EBITDA	(1.5)	(7.5)	(26.0)	45.4	14.1
EBIT	(2.0)	(14.6)	(38.1)	70.9	17.5
PAT	2.4	12.7	(40.5)	69.3	18.6
Quarterly (Rs mn)	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20
Revenue				7,413	7,413
Revenue	8,153	7,000	7,147	7,413 1,113	
Revenue EBITDA	8,153 1,229	7,000 1,059	7,147 1,052	7,413 1,113 15.0	1,826
Revenue	8,153	7,000	7,147 1,052 14.7	1,113 15.0	1,826 24.6
Revenue EBITDA EBITDA Margin (%)	8,153 1,229 15.1	7,000 1,059 15.1	7,147 1,052	1,113	7,413 1,826 24.6 1,379 8.7
Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs)	8,153 1,229 15.1 689	7,000 1,059 15.1 510	7,147 1,052 14.7 932	1,113 15.0 615	1,826 24.6 1,379
Revenue EBITDA EBITDA Margin (%) PAT	8,153 1,229 15.1 689	7,000 1,059 15.1 510	7,147 1,052 14.7 932	1,113 15.0 615	1,826 24.6 1,379 8.7
Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research	8,153 1,229 15.1 689 4.3	7,000 1,059 15.1 510 3.2	7,147 1,052 14.7 932 5.9	1,113 15.0 615 3.9	1,826 24.6 1,379 8.7 Mar-20
Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research Shareholding Pattern (%)	8,153 1,229 15.1 689 4.3 Mar-19	7,000 1,059 15.1 510 3.2 Jun-19	7,147 1,052 14.7 932 5.9 Sep-19	1,113 15.0 615 3.9 Dec-19	1,826 24.6 1,379
Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research Shareholding Pattern (%) Promoters	8,153 1,229 15.1 689 4.3 Mar-19 47.6	7,000 1,059 15.1 510 3.2 Jun-19 47.6	7,147 1,052 14.7 932 5.9 Sep-19 47.6	1,113 15.0 615 3.9 Dec-19 47.6	1,826 24.6 1,379 8.7 Mar-20 47.6


Source: Capitaline

RECOMMENDATION HISTORY TABLE

Date	Closing Price	TP (Period months)	Rating	Analyst
11-Feb-20	545	508	12m	Hold	Sanjeev Kumar Singh
23-Oct-19	562	572	12m	Hold	Sanjeev Kumar Singh
23-Sep-19	588	634	12m	Hold	Sanjeev Kumar Singh
23-Jul-19	511	540	12m	Hold	Sanjeev Kumar Singh
14-May-19	586	661	12m	Buy	Sanjeev Kumar Singh
12-Apr-19	622	665	12m	Buy	Sanjeev Kumar Singh
19-Jan-19	535	628	12m	Buy	Sanjeev Kumar Singh
16-Jan-19	535	628	12m	Buy	Sanjeev Kumar Singh
25-Oct-18	361	445	12m	Buy	Sanjeev Kumar Singh
24-Jul-18	434	509	12m	Accumulate	Sanjeev Kumar Singh
11-May-18	539	605	12m	Accumulate	Sanjeev Kumar Singh
30-Oct-17	684	670	12m	Hold	Amit Purohit
10-Aug-17	635	670	12m	Hold	Amit Purohit

Source: Company, Emkay Research

RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research



Analyst: Sanjeev Kumar Singh

Contact Details

sanjeev.singh@emkayglobal.com +91 22 6612 1255

Sector

Cement & Building materials

Analyst bio

Sanjeev Kumar Singh holds an MBA and has over 10 years of experience in the Cement sector. His team currently covers 17 stocks in the Cement and Building Materials space.

Emkay Alpha Portfolio – Cement & Building Materials

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight (Normalised)
Cement & Building Materials	2.14	2.14	0%	0	100.00
ACC	0.19	0.20	4%	1	9.22
Ambuja Cements	0.25	0.26	4%	1	11.97
Grasim Industries	0.43	0.23	-48%	-20	10.55
Birla Corporation	0.00	0.09	NA	9	4.11
India Cements	0.00	0.00	NA	0	0.00
JK Cement	0.00	0.00	NA	0	0.00
Jk Lakshmi Cement	0.00	0.12	NA	12	5.54
Orient Cement	0.00	0.00	NA	0	0.00
Prism Johnson	0.00	0.00	NA	0	0.00
Ramco Cements	0.14	0.10	-28%	-4	4.90
Sanghi Industries*	0.00	0.00	NA	0	0.00
Shree Cements	0.36	0.25	-31%	-11	11.52
Star Cement	0.00	0.00	NA	0	0.00
Ultratech Cement	0.77	0.90	17%	13	42.20
Century Plyboards	0.00	0.00	NA	0	0.00
Kajaria Ceramics	0.00	0.00	NA	0	0.00
Somany Ceramics	0.00	0.00	NA	0	0.00
Cash	0.00	0.00	NA	0	0.00

Source: Emkay Research

* Not under coverage: Equal Weight


High Conviction/Strong Over Weight

Sector portfolio NAV

	Base					Latest
	1-Apr-19	24-Sep-19	27-Dec-19	26-Mar-20	27-May-20	25-Jun-20
EAP - Cement & Building Materials	100.0	101.2	96.1	70.8	85.4	88.2
BSE200 Neutral Weighted Portfolio (ETF)	100.0	98.1	93.1	69.2	82.7	85.6

*Performance measurement base date 1st April 2019 Source: Emkay Research





Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): <u>SMID</u>

Please see our model portfolio (Emkay Alpha Portfolio): Nifty

"Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"

Emkay Rating Distribution

BUY Over 15%	
HOLD Between -5% to 15%	
SELL Below -5%	

Completed Date: 28 Jun 2020 00:50:11 (SGT) Dissemination Date: 28 Jun 2020 00:51:11 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

• This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

• Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investors. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate¹ does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of June 27, 2020
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report
- Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of June 27, 2020.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the June 27, 2020
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the June 27, 2020

RESTRICTIONS ON I	DISTRIBUTION
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Emkay Global Financial Services Ltd. CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com